Examiner-Initiated Interview Summary	Application No.	Applicant(s)
	10/576,408	BOSCHE ET AL.
	Examiner	Art Unit
	Andriae M. Holt	1616
All Participants:	Status of Application: 71	·
(1) <u>Andriae M. Holt</u> .	(3)	
(2) <u>Jessica Monachello, Attorney</u> .	(4)	
Date of Interview: 5 August 2010	Time: <u>11:00 a.m.</u>	
Type of Interview:	int's representative)	
Part I.		
Rejection(s) discussed:		
Claims discussed: 1, 4 and 11		
Prior art documents discussed: See Continuation Sheet		
Part II.		
SUBSTANCE OF INTERVIEW DESCRIBING THE GENER	RAL NATURE OF WHAT WAS	DISCUSSED:
Part III.		
 It is not necessary for applicant to provide a separate r directly resulted in the allowance of the application. The of the interview in the Notice of Allowability. It is not necessary for applicant to provide a separate r did not result in resolution of all issues. A brief summar 	e examiner will provide a writte ecord of the substance of the	en summary of the substance interview, since the interview
(A	.pplicant/Applicant's Representat	ive Signature – if appropriate)

Continuation of Identification of prior art discussed: The examiner contacted Ms. Monachello to discuss the claims in an effort to advance prosecution. The examiner indicted that claim 1 was still obvious over the prior art, but that claim 11 was a very specific claim that had been found to be free of the prior art and had allowable subject matter. Ms. Monachello indicated that she would be willing to accept the allowance of claim 11 if Ic claim 4 could be amended to depend on claim 11. The examiner would talk to her SPE to see if this amendment would be possible. 86/2010-The examiner contacted Ms. Monachello to let her know that the proposal to amend claim 4 to depend on claim 11 was acceptable. Ms. Monachello gave authorization on August 6, 2010 to execute an examiner's amendment to cancel claims 1 and 9-10; change the claim language of claim 4 to make it dependent on claim 11 and make the claim commensurate in scope with independent claim 11, i.e. adding the specific active agent and specific pharmaceutical excipients disclosed in claim 11; and add the terms "excluding starch" after carbohydrates in component e of claim 11.